8-K: Revvity Reports Strong Q4 and Full Year 2024 Results, Initiates 2025 Guidance

Revvity announced a 5% increase in fourth-quarter revenue and a full-year revenue of over $2.7 billion, alongside initiating full-year 2025 guidance.

Summary

• Revvity reported a fourth-quarter revenue of $729 million, representing a 5% reported growth and 6% organic growth.
• The company's GAAP earnings per share for the fourth quarter were $0.78, compared to $0.64 in the same period last year.
• Adjusted earnings per share from continuing operations for the fourth quarter were $1.42, up from $1.25 in the prior year.
• For the full year 2024, Revvity's GAAP revenue was $2,755 million, slightly up from $2,751 million in 2023.
• Full-year GAAP earnings per share were $2.20, down from $5.55 in 2023.
• Adjusted earnings per share for the full year were $4.90, compared to $4.65 in 2023.
• The company has initiated full-year 2025 guidance, forecasting total revenue of $2.80-$2.85 billion and adjusted earnings per share of $4.90-$5.00.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong Q4 results and positive 2025 guidance, although there are some concerns about the full-year GAAP EPS decline and the Life Sciences segment's performance.

Positives

• The company experienced strong revenue growth in the fourth quarter, with a 5% reported increase and 6% organic growth.
• Both GAAP and adjusted earnings per share increased in the fourth quarter compared to the same period last year.
• The Diagnostics segment saw a 4% increase in reported revenue and a 6% increase in organic revenue for the fourth quarter.
• The company's adjusted operating profit margin improved in both the fourth quarter and full year for both the Life Sciences and Diagnostics segments.
• Revvity has provided positive guidance for 2025, projecting revenue growth and increased adjusted earnings per share.

Negatives

• Full-year GAAP earnings per share decreased from $5.55 in 2023 to $2.20 in 2024.
• The Life Sciences segment experienced a 3% decrease in both reported and organic revenue for the full year 2024.
• The company's full-year adjusted operating income for the Life Sciences segment decreased from $489 million in 2023 to $448 million in 2024.

Risks

• The company's future performance is subject to various risks, including market declines, economic and political fluctuations, and the ability to introduce new products.
• There are risks associated with acquisitions and divestitures, including the ability to integrate acquired businesses and technologies successfully.
• The company faces risks related to competition, supply chain disruptions, and the retention of key personnel.
• Cybersecurity threats and the protection of intellectual property are also identified as potential risks.
• The company's ability to obtain future financing and comply with regulations are also listed as risks.

Future Outlook

Revvity forecasts total revenue of $2.80-$2.85 billion and adjusted earnings per share of $4.90-$5.00 for the full year 2025.

Management Comments

• Prahlad Singh, president and chief executive officer of Revvity, stated that the company finished last year on a strong note, positioning them well for 2025.
• He also expressed confidence that the full potential of Revvity will become more apparent as the company moves through the year following significant transformations.

Industry Context

This announcement reflects Revvity's performance in the health science solutions and diagnostics industry, where companies are focused on growth, innovation, and profitability. The company's focus on translational multi-omics technologies, biomarker identification, and diagnostics aligns with current industry trends.

Comparison to Industry Standards

• Revvity's 6% organic revenue growth in Q4 is a positive sign, indicating strong demand for its products and services, which is comparable to other companies in the life sciences and diagnostics sector such as Danaher and Thermo Fisher Scientific.
• The adjusted operating profit margin of 30.3% in Q4 is competitive, suggesting efficient cost management and profitability, which is in line with industry leaders like Agilent Technologies.
• The full-year adjusted EPS of $4.90 is a key metric for investors, and it will be compared against the performance of peers such as Illumina and Bio-Rad Laboratories to assess Revvity's relative value.
• The company's 2025 guidance for revenue between $2.80 and $2.85 billion and adjusted EPS between $4.90 and $5.00 will be closely watched by analysts and investors to see if Revvity can maintain its growth trajectory.

Stakeholder Impact

• Shareholders will likely react positively to the strong Q4 results and 2025 guidance.
• Employees may be encouraged by the company's positive performance and future outlook.
• Customers should benefit from the company's continued investment in innovation and product development.
• Suppliers and creditors will likely view the company's financial stability favorably.

Next Steps

• The company will discuss its fourth quarter and full year 2024 results and its outlook for business trends during a webcast on January 31, 2025.
• The company will continue to focus on its strategic initiatives and growth opportunities in the health science solutions market.

Key Dates

Keywords

Revvity, Financial Results, Earnings, Revenue, EPS, Guidance, Life Sciences, Diagnostics, Organic Growth, Adjusted Operating Income